DEF 14A: T2 Biosystems Seeks Stockholder Approval for CRG Debt-to-Equity Conversion

T2 Biosystems is asking stockholders to approve a debt-to-equity conversion with CRG that could result in CRG owning a significant portion of the company's common stock.

Summary

• T2 Biosystems is holding a special meeting of stockholders on April 11, 2024, to vote on a proposal to approve a debt-to-equity conversion with CRG.
• The proposal involves the potential future cancellation of $15 million of outstanding loans under the CRG Term Loan Agreement in exchange for shares of Common Stock.
• The price per share will be the lower of the average closing price for the five days preceding the issuance or the closing price on the day immediately preceding the issuance.
• If the conversion would result in CRG owning more than 49.99% of the Common Stock (or 9.99% for one of the CRG funds), Convertible Preferred Stock will be issued instead.
• Stockholder approval is required because the conversion could result in CRG beneficially owning more than 19.99% of the outstanding Common Stock, exceeding the Beneficial Ownership Limitation.
• Approval is also needed because the issuance price may be less than the Nasdaq Minimum Price.
• As of December 31, 2023, T2 Biosystems had $41,284,000 in outstanding principal amount of loans under the CRG Term Loan Agreement.
• As of December 31, 2023, CRG beneficially owned 93,297 shares of Series B Convertible Preferred Stock convertible into 932,970 shares of Common Stock.
• If the conversion is not approved, CRG will not be able to exchange their debt for shares of Common Stock if such conversion would result in CRG owning more than the Beneficial Ownership Limitation or the Price Per Share is less than the Nasdaq Minimum Price.
• The Board of Directors recommends that stockholders vote FOR the approval of the CRG Debt to Equity Conversion.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed debt-to-equity conversion. The outcome depends on stockholder approval and the subsequent impact on the company's capital structure.

Positives

• CRG agreed to waive prepayment premiums and back-end fees associated with the principal amounts of loans exchanged for equity.
• The Board of Directors believes that the Securities Purchase Agreement and the transactions contemplated thereunder are in the best interests of the Company and its stockholders.

Negatives

• If approved, CRG could own a substantial percentage of shares of Common Stock that may be voted without restriction.
• If the CRG Debt Conversion is not approved, CRG will not be able to exchange their debt for shares of Common Stock if such conversion would result in CRG owning more than the Beneficial Ownership Limitation or the Price Per Share is less than the Nasdaq Minimum Price.

Risks

• If stockholders do not approve the CRG Debt Conversion, the company may face challenges in managing its debt obligations.
• The conversion could result in a significant change in the company's ownership structure.
• The price per share for the conversion could be lower than the Nasdaq Minimum Price, potentially diluting existing shareholders.
• The company's reliance on CRG for financing could create a dependency that limits its strategic flexibility.

Future Outlook

The company is seeking stockholder approval to proceed with the CRG Debt Conversion, which could significantly impact its capital structure and ownership.

Management Comments

• Our Board of Directors determined that the Securities Purchase Agreement and the transactions contemplated thereunder, and the issuance of shares as contemplated under the CRG Debt Conversion is in the best interests of our Company and its stockholders.

Industry Context

Debt-to-equity conversions are a common strategy for companies facing financial challenges, particularly in the biotech and healthcare sectors. These conversions can help reduce debt burden and improve balance sheets, but they also dilute existing shareholders.

Comparison to Industry Standards

• Similar debt-to-equity conversions have been observed in other small-cap biotech companies facing liquidity constraints.
• The terms of the CRG Term Loan Agreement, including interest rates and amendment fees, appear to be within the typical range for venture debt financing in the life sciences industry.
• The potential ownership stake that CRG could acquire is significant and warrants careful consideration by stockholders, as it could impact the company's future strategic direction.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution of their ownership if the debt is converted to equity.
• The company's financial stability could be improved if the debt burden is reduced.
• Employees may be affected by any strategic changes resulting from the conversion.

Next Steps

• Stockholders will vote on the CRG Debt to Equity Conversion proposal at the Special Meeting on April 11, 2024.
• The company will proceed with the conversion if the proposal is approved.
• The company will continue to operate under the terms of the CRG Term Loan Agreement if the proposal is not approved.

Key Dates

Keywords

CRG, debt-to-equity conversion, stockholder approval, common stock, convertible preferred stock, Nasdaq Listing Rules, Securities Purchase Agreement, T2 Biosystems, debt financing